Skip to main content
CDC Website

Researchers

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

Co-infection and Cancer (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms.

Co-infection and Cancer (R01 Clinical Trial Not Allowed)

This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to co-infections (excluding co-infection with human immunodeficiency virus [HIV]) that engendered novel opportunities for prevention and treatment and focus on understudied populations.

NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID.

Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing.

HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)

The purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as preclinical models.

Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of their residency training but who have at least two years of postdoctoral experience.

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities.

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities.